Recombinant Mouse CXCL10/IP-10 protein (rFc Tag) (HPLC verified)

Species

Mouse

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg5063



Product Information

Purity >90 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse CXCL10 protein Ile22-Pro98 (Accession# Q548V9) with a rabbit IgG Fc tag at the C-terminus
GeneID 15945
Accession Q548V9
PredictedSize 35.0 kDa
SDS-PAGE 28-35 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CXCL10 ( also known as IP-10) is a member of the CXC chemokine family which binds to the CXCR3 receptor to exert its biological effects. CXCL10 is a 12-kDa protein and constitutes two internal disulfide cross bridges. The predicted signal peptidase cleavage generates a 10-kDa secreted polypeptide with four conserved cysteine residues in the N-terminal. The CXCL10 gene localizes on chromosome 4 at band q21, a locus associated with an acute monocytic/B-lymphocyte lineage leukemia exhibiting translocation of t (4; 11) (q21; q23). CXCL10 mediates leukocyte trafficking, adaptive immunity, inflammation, haematopoiesis and angiogenesis. Under proinflammatory conditions CXCL10 is secreted from a variety of cells, such as leukocytes, activated neutrophils, eosinophils, monocytes, epithelial cells, endothelial cells, stromal cells (fibroblasts) and keratinocytes in response to IFN-γ.

References:

1.Liu M. etal. (2011). Oncol Lett. 2(4):583-589. 2.Walser TC. etal. (2006). Cancer Res. 66(15):7701-7. 3.Luster AD. et al. (1987). J ExpMed. 166(4):1084-97. 4.Lo BK. etal. (2010). Am JPathol. 176(5):2435-46. 5.GroomJR.Etal. (2011). ImmunolCe lBiol. 89(2):207-15.